AU2001228825A1 - Remedies - Google Patents

Remedies

Info

Publication number
AU2001228825A1
AU2001228825A1 AU2001228825A AU2882501A AU2001228825A1 AU 2001228825 A1 AU2001228825 A1 AU 2001228825A1 AU 2001228825 A AU2001228825 A AU 2001228825A AU 2882501 A AU2882501 A AU 2882501A AU 2001228825 A1 AU2001228825 A1 AU 2001228825A1
Authority
AU
Australia
Prior art keywords
growth factor
nerve growth
factor production
enhancing
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228825A
Other languages
English (en)
Inventor
Suzu Deguchi
Ikunoshin Kato
Eiji Kobayashi
Tuo-Ping Li
Eiji Nishiyama
Hiromu Ohnogi
Hiroaki Sagawa
Masahiro Shiraga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Shuzo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co Ltd filed Critical Takara Shuzo Co Ltd
Publication of AU2001228825A1 publication Critical patent/AU2001228825A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001228825A 2000-01-27 2001-01-26 Remedies Abandoned AU2001228825A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2000019331 2000-01-27
JP2000-19331 2000-01-27
JP2000019208 2000-01-27
JP2000-19208 2000-01-27
JP2000254683 2000-08-24
JP2000-254683 2000-08-24
JP2000-308519 2000-10-06
JP2000308519 2000-10-06
PCT/JP2001/000513 WO2001054682A1 (fr) 2000-01-27 2001-01-26 Medicaments

Publications (1)

Publication Number Publication Date
AU2001228825A1 true AU2001228825A1 (en) 2001-08-07

Family

ID=27480961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228825A Abandoned AU2001228825A1 (en) 2000-01-27 2001-01-26 Remedies

Country Status (10)

Country Link
US (1) US7268160B2 (de)
EP (1) EP1254658B1 (de)
JP (1) JP4249926B2 (de)
KR (2) KR20060095786A (de)
CN (1) CN100346776C (de)
AT (1) ATE409028T1 (de)
AU (1) AU2001228825A1 (de)
DE (1) DE60135904D1 (de)
TW (1) TWI255181B (de)
WO (1) WO2001054682A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127572A3 (de) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten
CN1436074A (zh) * 2000-04-11 2003-08-13 宝生物工程株式会社 治疗剂
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7361774B2 (en) 2002-10-01 2008-04-22 Takara Bio Inc. Chalcone compound
WO2004043475A1 (ja) * 2002-11-12 2004-05-27 Takara Bio Inc. 学習・記憶能力の向上剤
WO2004096198A1 (ja) * 2003-05-02 2004-11-11 Takara Bio Inc. 治療剤
JPWO2005054170A1 (ja) * 2003-12-05 2007-12-06 タカラバイオ株式会社 治療剤
WO2005074906A1 (ja) * 2004-02-06 2005-08-18 Takara Bio Inc. 治療剤
EP1883453A1 (de) * 2005-05-26 2008-02-06 Council Of Scientific And Industrial Research Pharmazeutische zusammensetzung mit eignung bei der behandlung von hepatozellulärem karzinom
JP2007230946A (ja) * 2006-03-02 2007-09-13 Nagase & Co Ltd 神経突起伸長剤
JP4912708B2 (ja) * 2006-03-24 2012-04-11 三井農林株式会社 新規物質ｔｍｒ
EP2173697A1 (de) * 2007-07-25 2010-04-14 Symrise GmbH & Co. KG 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanon und dessen verwendung als antioxidationsmittel
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2017043572A (ja) * 2015-08-28 2017-03-02 株式会社ファンケル ヘリピロンａを有効成分とするｂｄｎｆ産生促進剤
CN109651121B (zh) * 2019-01-25 2021-11-26 陕西理工大学 一种Robtein的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3761471A (en) * 1970-11-16 1973-09-25 Tamio Nishimura Benzalacetone or acetophenone amidinohydrazone derivatives and the production thereof
FI874163A (fi) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
JPS6442422A (en) * 1987-08-10 1989-02-14 Tsumura & Co Antiulcer agent
US5234951A (en) * 1986-12-12 1993-08-10 Tsumura Juntendo, Inc. Anti-ulcer agent comprising chalcone derivative
KR890700117A (ko) * 1986-12-12 1989-03-02 쓰무라 아끼라 유효성분으로서 칼콘 유도체를 함유하는 항 궤양제 및 신규의 칼콘 유도체
JPH01125320A (ja) * 1987-11-09 1989-05-17 Tsumura & Co テストステロン−５α−リダクターゼ阻害剤
JPH02104568A (ja) 1988-06-22 1990-04-17 Yoshitomi Pharmaceut Ind Ltd 神経成長因子産生促進作用剤
JPH02187765A (ja) * 1989-01-14 1990-07-23 Oki Electric Ind Co Ltd コントラスト増強用の光脱色性層用材料およびそれを用いたパターン形成方法
JPH08768B2 (ja) * 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
JPH03122645A (ja) * 1989-10-05 1991-05-24 Nippon Kanko Shikiso Kenkyusho:Kk ホトレジスト用光吸収材料
JP2719042B2 (ja) 1990-11-22 1998-02-25 三共株式会社 神経成長因子産生分泌促進剤
JPH07110812B2 (ja) 1990-12-11 1995-11-29 財団法人喫煙科学研究財団 神経成長因子生合成促進剤
JPH0578384A (ja) * 1991-03-27 1993-03-30 Taisho Pharmaceut Co Ltd フラボノール誘導体
JPH0561220A (ja) * 1991-08-30 1993-03-12 Ricoh Co Ltd 電子写真感光体
JPH05246932A (ja) * 1992-03-04 1993-09-24 Nippon High Potsukusu:Kk ３，４−ジヒドロキシカルコン誘導体
JPH07194355A (ja) * 1993-12-28 1995-08-01 Sanei Gen F F I Inc エタノール製剤
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
JPH0827086A (ja) 1994-07-22 1996-01-30 Sagami Chem Res Center Ｎ−アシル−ｎ−置換シンナモイルエチレンジアミン誘導体
FR2747568B1 (fr) * 1996-04-17 1999-09-17 Oreal Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux
JPH10114649A (ja) * 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk 津液改善剤及びそれを含有する経口投与用組成物
GB9712966D0 (en) 1997-06-19 1997-08-27 Indena Spa Novel chalcones
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
EP0998939A1 (de) * 1998-09-09 2000-05-10 The School Of Pharmacy, University Of London Chalcone Pflanzenextrakten zur Anwendung in der Therapie
CN1213744C (zh) 1999-02-19 2005-08-10 宝生物工程株式会社 药物
WO2000062785A1 (fr) * 1999-04-15 2000-10-26 Takara Shuzo Co., Ltd. Remedes
AU2300001A (en) * 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Also Published As

Publication number Publication date
KR20020073186A (ko) 2002-09-19
WO2001054682A1 (fr) 2001-08-02
EP1254658A1 (de) 2002-11-06
CN1419448A (zh) 2003-05-21
US7268160B2 (en) 2007-09-11
US20030144316A1 (en) 2003-07-31
JP4249926B2 (ja) 2009-04-08
EP1254658A4 (de) 2003-06-18
KR100711537B1 (ko) 2007-04-27
TWI255181B (en) 2006-05-21
CN100346776C (zh) 2007-11-07
DE60135904D1 (de) 2008-11-06
ATE409028T1 (de) 2008-10-15
EP1254658B1 (de) 2008-09-24
KR20060095786A (ko) 2006-09-01

Similar Documents

Publication Publication Date Title
AU2001228825A1 (en) Remedies
EP1247456A3 (de) Wohlschmeckende pharmazeutische Zusammensetzung für Haustiere
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1232757A4 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
BG105459A (en) Pharmaceutical moxifloxacin preparation
WO2005030753A3 (en) Therapeutic agents useful for treating pain
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
EP1356811A4 (de) Prophylaktika oder heilmittel für arthritis
PL342614A1 (en) Anticarcinogenic drugs
CA2298645A1 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
WO2002070464A3 (en) Hydrazones and their therapeutic use
AU693833B2 (en) Products containing G-CSF and TNF binding protein
WO2001097793A3 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2001072685A3 (en) Polyamine analogues as cytotoxic agents
CA2429793A1 (en) Interferon therapeutic effect enhancer
EP1354584A4 (de) Präventiva für arthritis
HK1085744A1 (en) Steroid compounds with anti-tumor activity
WO2001030328A3 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
WO2002046163A3 (de) Chinolin-derivative und ihre verwendung als antiepileptika
EP1232748A4 (de) Subsituierte nitrobenzol derivate mit medikamentöser oder anderer wirkung
WO2003029495A3 (de) Coniosulfide und deren derivate, verfahren zur ihrer herstellung und verwendung als arzneimittel